First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

Abstract ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator (ICOS) pathways simultaneously. A first‐in‐human stud...

Full description

Bibliographic Details
Main Authors: Jing Yang, Jason D. Lickliter, Jan L. Hillson, Gary D. Means, Russell J. Sanderson, Kay Carley, Almudena Tercero, Kristi L. Manjarrez, Jennifer R. Wiley, Stanford L. Peng
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12983

Internet

https://doi.org/10.1111/cts.12983

Similar Items